Modified Coxsackievirus Genome Used as Attenuated Vaccine Viral Vector Inserting the Coxsackievirus Genome and Vaccine Composition Containing the Viral Vector

摘要

A modified coxsackievirus genome used as an attenuated vaccine is provided to reduce toxicity of coxsackievirus compared to the wild type by modifying some nucleotides, and produce the amount of antibodies similar as that of the wild type, so that disease caused by coxsackievirus is prevented. A modified coxsackievirus genome used as an attenuated vaccine in which the nucleotide encoding at least one tyrosine of ITAM(Immunoreceptor Tyrosine-based Activation sequence Motif) sequence of capsid protein expressed from the coxsackievirus genome is modified by the nucleotide encoding other amino acid is provided, wherein the ITAM sequence is present in VP2 region of coxsackievirus; the nucleotide encoding tyrosine is substituted by the nucleotide encoding phenylalanine; and the modified coxsackievirus genome is derived from CVB1, CVB2, CVB3, CVB4 and CVB5 and comprises the nucleotide sequence encoding modified VP2 peptide having the amino acid sequences of SEQ ID NO:13, 15 or 17 or the nucleotide sequence of SEQ ID NO:14, 16 or 18. The recombinant viral vector contains the modified coxsackievirus genome, at least one cloning site, at least one antibiotic-resistant gene and at least one replication origin. The vaccine composition comprises the recombinant viral vector and pharmaceutically acceptable carriers.